Insulin glargine, a long-acting insulin analog, is essential in managing diabetes, providing steady glucose control over 24 hours. As diabetes cases continue to rise globally, biosimilars of insulin glargine have emerged as affordable alternatives to branded products like Sanofi’s Lantus, reducing the financial burden on healthcare systems and patients alike. Market Outlook for Insulin...